AR078818A1 - DERIVATIVES OF AZAINDOL - Google Patents
DERIVATIVES OF AZAINDOLInfo
- Publication number
- AR078818A1 AR078818A1 ARP100103979A ARP100103979A AR078818A1 AR 078818 A1 AR078818 A1 AR 078818A1 AR P100103979 A ARP100103979 A AR P100103979A AR P100103979 A ARP100103979 A AR P100103979A AR 078818 A1 AR078818 A1 AR 078818A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- alkoxy
- cycloalkyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Abstract
Composiciones que comprenden dichos compuestos; el uso de dichos compuestos en terapia (tal como asma o EPOC); y métodos para tratar pacientes con tales compuestos. Reivindicacion 1: Un compuesto de formula (1) en donde R1 y R2 se seleccionan independientemente de H, hidroxilo, alquilo C1-10, alcoxi C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4 y heteroariloalquilo C1-4; R3 se selecciona de H, alquilo C1-10 y alquenilo C2-6; R4 y R5 se seleccionan independientemente de H y alquilo C1-6; A1 se selecciona de CR6 y S(O)R7; R6 se selecciona de R7 y los grupos de las formulas (2), (3) y (4); R7 se selecciona de alquilo C1-6, alquenilo C2-6, cicloalquilo C3-10, arilo, y ariloalquilo C1-4; R8 y R9 se seleccionan independientemente de H, alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4 y heteroariloalquilo C1-4; R10 y R11 se seleccionan independientemente de H, alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4, ariloalquenilo C2-4, heteroariloalquilo C1-4, -SO2alquilo C1-6, -SO2arilo y -SO2ariloalquilo C1-4; o R10 y R11 junto con el átomo de nitrogeno al que están unidos pueden formar un anillo de 4-7 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN e hidroxilo; dicho anillo que contiene N puede también estar opcionalmente fusionado a un grupo arilo; o R8 y R10 junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente insaturado de 4-7 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido en el carbono con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN e hidroxilo; o R9 está ausente y R8 y R10 junto con los átomos a los que están unidos pueden formar un anillo aromático mono o bicíclico de 5, 6, 9 o 10 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido en el carbono con 1, 2 o 3 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN, arilo, COOR15 e hidroxilo; o R8 y R10 juntos pueden formar un grupo de acuerdo con formula (5) o formula (6); R12 y R13 se seleccionan independientemente de H, alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4, ariloalquenilo C2-4, heteroariloalquilo C1-4, -SO2alquilo C1-6, -SO2arilo y SO2ariloalquilo C1-4; Ra y Rb se seleccionan independientemente de H, alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4, ariloalquenilo C2-4, heteroariloalquilo C1-4, -SO2alquilo C1-6, -SO2arilo y SO2ariloalquilo C1-4; o Ra y Rb junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente insaturado de 4-7 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido con carbono con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN e hidroxilo; dicho anillo que contiene N puede también estar opcionalmente fusionado a un grupo arilo; o Ra y Rb junto con los átomos a los que están unidos pueden formar un anillo aromático mono o bicíclico de 5, 6, 9 o 10 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido con carbono con 1, 2 o 3 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN, arilo, COOR15 e hidroxilo; R14 se selecciona de H, alquilo C1-6, alcoxi C1-6, OH, CN, CF3, COOR15, halo y NR15R16; R15 y R16 se seleccionan independientemente de H y alquilo C1-6; R17, R18 R19 y R20 se seleccionan independientemente de H, hidroxilo, halo, CN, alquilo C1-10 y alcoxi C1-6; f y g se seleccionan independientemente de 0, 1, 2 y 3, de manera tal que f+ g=1, 2 o 3; h se selecciona de 1 y 2; en donde: alquilo puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, alcoxi C1-6, OH, CN, CF3, COOR15, fluoro y NR15R16; alquenilo puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, alcoxi C1-6, OH, CN, CF3, COOR15, fluoro y NR15R16; alquinilo puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, alcoxi C1-6, OH, CN, CF3, COOR11, fluoro y NR11R12; alcoxi puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, OH, CN, CF3, COOR15, fluoro y NR15R16; cicloalquilo es un anillo hidrocarburo mono o bicíclico no aromático, opcionalmente fusionado a un grupo arilo, en donde dicho anillo cicloalquilo contiene opcionalmente, cuando es posible, hasta 2 enlaces dobles; y en donde, a menos que se especifique lo contrario, dicho cicloalquilo puede estar opcionalmente sustituido por 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, CN, CF3, COOR15, fluoro y NR15R16; heterocicloalquilo es un anillo mono o bicíclico, no aromático de 3 a 10 miembros unido a C o unido a N, en donde dicho anillo heterocicloalquilo contiene, cuando es posible, 1, 2 o 3 heteroátomos independientemente seleccionados de N, NR15, S(O)q y O; y dicho anillo heterocicloalquilo contiene opcionalmente, cuando es posible, 1 o 2 enlaces dobles, y está opcionalmente sustituido en el carbono con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, CN, CF3, halo, COOR15, NR15R16 y arilo; arilo es un sistema de anillos aromático simple o fusionado que contiene de 6 o 10 átomos de carbono; en donde, a menos que se especifique lo contrario, cada aparicion de arilo puede estar opcionalmente sustituida con hasta 5 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, halo, CN, COOR15, CF3 y NR15R16; heteroarilo es un anillo aromático mono o bicíclico de 5, 6, 9 o 10 miembros, que contiene, cuando es posible, 1, 2 o 3 miembros del anillo independientemente seleccionados de N, NR15, S y O; en donde, a menos que se especifique lo contrario, dicho heteroarilo puede estar opcionalmente sustituido con 1, 2 o 3 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, halo, CN, COOR11, CF3 y NR15R16; q es 0, 1 o 2; y tautomeros, estereoisomeros, sales y solvatos farmacéuticamente aceptables del mismo.Compositions comprising said compounds; the use of said compounds in therapy (such as asthma or COPD); and methods to treat patients with such compounds. Claim 1: A compound of formula (1) wherein R1 and R2 are independently selected from H, hydroxy, C1-10 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylC 1-4 alkyl and heteroarylC 1-4 alkyl; R3 is selected from H, C1-10 alkyl and C2-6 alkenyl; R4 and R5 are independently selected from H and C1-6 alkyl; A1 is selected from CR6 and S (O) R7; R6 is selected from R7 and the groups of the formulas (2), (3) and (4); R 7 is selected from C 1-6 alkyl, C 2-6 alkenyl, C 3-10 cycloalkyl, aryl, and C 1-4 arylalkyl; R8 and R9 are independently selected from H, C1-10 alkyl, C2-6 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-4 arylalkyl and C1-4 heteroarylalkyl; R10 and R11 are independently selected from H, C1-10 alkyl, C2-6 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-4 arylalkyl, C2-4 arylalkenyl, C1-4 heteroarylalkyl, C1-6 alkyl , -SO2aryl and -SO2-C1-4alkylalkyl; or R10 and R11 together with the nitrogen atom to which they are attached can form a 4-7 membered ring containing N, which optionally contains another heteroatom selected from N, O and S, and optionally substituted with 1 or 2 independently selected substituents C1-6 alkyl, C1-6 alkoxy, halo, CN and hydroxyl; said ring containing N may also be optionally fused to an aryl group; or R8 and R10 together with the atoms to which they are attached can form a 4-7 membered saturated or partially unsaturated ring containing N, optionally containing another heteroatom selected from N, O and S, and optionally substituted on the carbon with 1 or 2 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, halo, CN and hydroxyl; or R9 is absent and R8 and R10 together with the atoms to which they are attached can form a mono, bicyclic aromatic ring of 5, 6, 9 or 10 members containing N, optionally containing another heteroatom selected from N, O and S , and optionally substituted on carbon with 1, 2 or 3 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, halo, CN, aryl, COOR15 and hydroxyl; or R8 and R10 together can form a group according to formula (5) or formula (6); R12 and R13 are independently selected from H, C1-10 alkyl, C2-6 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-4 arylalkyl, C2-4 arylalkenyl, C1-4 heteroarylalkyl, C1-6 alkyl , -SO2aryl and SO2arylC 1-4 alkyl; Ra and Rb are independently selected from H, C1-10 alkyl, C2-6 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-4 arylalkyl, C2-4 arylalkenyl, C1-4 heteroarylalkyl, C1-6 alkyl , -SO2aryl and SO2arylC 1-4 alkyl; or Ra and Rb together with the atoms to which they are attached can form a 4-7 membered saturated or partially unsaturated ring containing N, optionally containing another heteroatom selected from N, O and S, and optionally substituted with carbon with 1 or 2 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, halo, CN and hydroxyl; said ring containing N may also be optionally fused to an aryl group; or Ra and Rb together with the atoms to which they are attached can form a mono, bicyclic, 5, 6, 9 or 10-membered aromatic ring containing N, optionally containing another heteroatom selected from N, O and S, and optionally substituted with carbon with 1, 2 or 3 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, halo, CN, aryl, COOR15 and hydroxyl; R14 is selected from H, C1-6 alkyl, C1-6 alkoxy, OH, CN, CF3, COOR15, halo and NR15R16; R15 and R16 are independently selected from H and C1-6 alkyl; R17, R18 R19 and R20 are independently selected from H, hydroxyl, halo, CN, C1-10 alkyl and C1-6 alkoxy; f and g are independently selected from 0, 1, 2 and 3, such that f + g = 1, 2 or 3; h is selected from 1 and 2; wherein: alkyl may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, C1-6 alkoxy, OH, CN, CF3, COOR15, fluoro and NR15R16; alkenyl may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, C1-6 alkoxy, OH, CN, CF3, COOR15, fluoro and NR15R16; alkynyl may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, C1-6 alkoxy, OH, CN, CF3, COOR11, fluoro and NR11R12; Alkoxy may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, OH, CN, CF3, COOR15, fluoro and NR15R16; cycloalkyl is a non-aromatic mono or bicyclic hydrocarbon ring, optionally fused to an aryl group, wherein said cycloalkyl ring optionally contains, when possible, up to 2 double bonds; and wherein, unless otherwise specified, said cycloalkyl may be optionally substituted by 1 or 2 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, CN, CF3, COOR15, fluoro and NR15R16; heterocycloalkyl is a mono or bicyclic, non-aromatic 3 to 10 membered ring attached to C or attached to N, wherein said heterocycloalkyl ring contains, when possible, 1, 2 or 3 heteroatoms independently selected from N, NR15, S (O ) q and O; and said heterocycloalkyl ring optionally contains, when possible, 1 or 2 double bonds, and is optionally substituted on the carbon with 1 or 2 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, CN, CF3, halo, COOR15, NR15R16 and aryl; aryl is a simple or fused aromatic ring system containing 6 or 10 carbon atoms; wherein, unless otherwise specified, each occurrence of aryl may be optionally substituted with up to 5 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, halo, CN, COOR15, CF3 and NR15R16; heteroaryl is a mono, bicyclic aromatic ring of 5, 6, 9 or 10 members, containing, when possible, 1, 2 or 3 ring members independently selected from N, NR15, S and O; wherein, unless otherwise specified, said heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, halo, CN, COOR11, CF3 and NR15R16; q is 0, 1 or 2; and pharmaceutically acceptable tautomers, stereoisomers, salts and solvates thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25561009P | 2009-10-28 | 2009-10-28 | |
| GBGB0918924.2A GB0918924D0 (en) | 2009-10-28 | 2009-10-28 | Azaindole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078818A1 true AR078818A1 (en) | 2011-12-07 |
Family
ID=41434816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103979A AR078818A1 (en) | 2009-10-28 | 2010-10-28 | DERIVATIVES OF AZAINDOL |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR078818A1 (en) |
| GB (1) | GB0918924D0 (en) |
| TW (1) | TW201120038A (en) |
| UY (1) | UY32976A (en) |
| WO (1) | WO2011051672A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| AU2019462669A1 (en) * | 2019-08-21 | 2022-02-24 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0147716A3 (en) | 1983-12-24 | 1987-10-28 | ANT Nachrichtentechnik GmbH | Method and apparatus for the encipherable transmission of a series of binary information signals with authenticity check |
| JPS6235216A (en) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | Method and device for measuring thickness of heterogeneous material layer nondestructively |
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GR1001529B (en) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Process for the obtainment of a new pregna-1,4-diene-3,20-dione -16-17-acetal-21 esters |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| WO1993018007A1 (en) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Novel carbostyril derivative |
| SE9301911D0 (en) | 1993-06-03 | 1993-06-03 | Ab Astra | NEW PEPTIDE DERIVATIVES |
| US5464820A (en) | 1993-06-22 | 1995-11-07 | The University Hospital | Specific inhibitors of tissue kallikrein |
| GB9318637D0 (en) | 1993-09-08 | 1993-10-27 | Ferring Res Ltd | Enzyme inhibitors |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| EP1305300A1 (en) | 2000-04-27 | 2003-05-02 | Boehringer Ingelheim Pharma GmbH & Co.KG | Novel, slow-acting betamimetics, a method for their production and their use as medicaments |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| ATE365720T1 (en) | 2001-03-08 | 2007-07-15 | Glaxo Group Ltd | AGONISTS OF BETA-ADRENORECEPTORS |
| JP4143413B2 (en) | 2001-03-22 | 2008-09-03 | グラクソ グループ リミテッド | Formanilide derivatives as β2-adrenergic receptor agonists |
| EP1425001B1 (en) | 2001-09-14 | 2008-12-17 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| DE60214428T2 (en) | 2001-12-20 | 2007-09-20 | Bayer Healthcare Ag | 1, 4-DIHYDRO-1, 4-DIPHENYLPYRIDINE DERIVATIVES |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| GB0205527D0 (en) * | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| US7271197B2 (en) | 2002-04-25 | 2007-09-18 | Glaxo Group Limited | Phenethanolamine derivatives |
| US6747043B2 (en) | 2002-05-28 | 2004-06-08 | Theravance, Inc. | Alkoxy aryl β2 adrenergic receptor agonists |
| WO2003101941A2 (en) | 2002-05-31 | 2003-12-11 | Genzyme Corporation | Alpha acyloxyacetamides for kallikrein and urokinase inhibition |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| PE20050130A1 (en) | 2002-08-09 | 2005-03-29 | Novartis Ag | ORGANIC COMPOUNDS |
| AU2003293356A1 (en) | 2002-08-27 | 2004-03-19 | Bayer Healthcare Ag | Dihydropyridinone derivatives as hne inhibitors |
| GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| US7687510B2 (en) | 2002-09-10 | 2010-03-30 | Bayer Healthcare Ag | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes |
| EP1539710B1 (en) | 2002-09-10 | 2010-10-27 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclic derivatives |
| DE10246374A1 (en) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 4-(2-alkylamino-1-hydroxyethyl)-3-alkoxy-benzene-1,2-diol derivatives, are beta-mimetics having a long duration of action, useful e.g. for treating asthma, chronic obstructive pulmonary disease or arrhythmia |
| CA2499314C (en) | 2002-10-11 | 2010-08-24 | Pfizer Inc. | Indole derivatives as beta-2 agonists |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| ATE369353T1 (en) | 2002-10-22 | 2007-08-15 | Glaxo Group Ltd | MEDICALLY USABLE ARYLETHANOLAMINE COMPOUNDS |
| ES2302956T3 (en) | 2002-10-28 | 2008-08-01 | Glaxo Group Limited | DERIVED FROM PHENETHANOLAMINE FOR THE TREATMENT OF RESPIRATORY DISEASES. |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| JP2004161702A (en) | 2002-11-14 | 2004-06-10 | Hokko Chem Ind Co Ltd | METHOD FOR PRODUCING gamma-JASMOLACTONE |
| DE10253282A1 (en) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| DE10253220A1 (en) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 2-(N-phenylalkyl-amino)-1-phenyl-ethanol derivatives, are beta-adrenergic agents especially useful for treating inflammatory and obstructive respiratory diseases such as asthma or COPD |
| DE10258695A1 (en) | 2002-12-16 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 2-(2-hydroxy-2-(3-methylsulfonylamino-4-hydroxyphenyl)ethylamino-4-(pyrid-2-ylamino)-2-methylbutane used e.g. for treating asthma and chronic obstructive pulmonary disease |
| GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| WO2004089892A2 (en) | 2003-04-01 | 2004-10-21 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity |
| EP1613315B1 (en) | 2003-04-04 | 2009-01-21 | Novartis AG | Quinoline-2-one-derivatives for the treatment of airways diseases |
| US7268147B2 (en) | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
| US7358244B2 (en) | 2003-05-28 | 2008-04-15 | Theravance, Inc. | Azabicycloalkane compounds |
| WO2004108675A1 (en) | 2003-06-04 | 2004-12-16 | Pfizer Limited | 2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists |
| GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| SE0302324D0 (en) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302323D0 (en) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| SE0302487D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| WO2005033121A2 (en) | 2003-10-03 | 2005-04-14 | King Pharmaceuticals Research & Development, Inc. | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs |
| GB0323701D0 (en) | 2003-10-09 | 2003-11-12 | Glaxo Group Ltd | Formulations |
| GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| WO2005041980A1 (en) | 2003-11-03 | 2005-05-12 | Ivax Corporation | Soft steroid compositions for use in dry powder inhalers |
| GB0328490D0 (en) | 2003-12-09 | 2004-01-14 | Glaxo Group Ltd | Medicinal compounds |
| GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
| US7807046B2 (en) | 2003-12-19 | 2010-10-05 | Shell Oil Company | Systems, methods, and catalysts for producing a crude product |
| DE102004001413A1 (en) | 2004-01-09 | 2005-08-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of chronic obstructive pulmonary disease |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| DE602005001929T2 (en) | 2004-01-22 | 2007-12-06 | Pfizer Inc. | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES |
| CA2553789C (en) | 2004-01-22 | 2011-07-19 | Pfizer Inc. | Sulfonamide derivatives for the treatment of diseases |
| DE102004003428A1 (en) | 2004-01-23 | 2005-08-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New long-acting beta-2 agonists, and their use as pharmaceuticals |
| ES2349470T3 (en) | 2004-02-14 | 2011-01-03 | Boehringer Ingelheim International Gmbh | NEW BETA-2-AGONISTS OF LONG-TERM ACTION AND ITS USE AS MEDICATIONS. |
| ATE516285T1 (en) | 2004-02-19 | 2011-07-15 | Bayer Schering Pharma Ag | DIHYDROPYRIDINONE DERIVATIVES |
| US7893073B2 (en) | 2004-02-26 | 2011-02-22 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclic derivatives |
| JP4825194B2 (en) | 2004-02-26 | 2011-11-30 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 1,4-Diaryl-dihydropyrimidin-2-one compounds and their use as human neutrophil elastase inhibitors |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| EP1577292A1 (en) | 2004-03-17 | 2005-09-21 | Pfizer Limited | Phenylaminoethanol derivatives as beta2 receptor agonists |
| EP1577306A1 (en) | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases |
| HN2004000023A (en) | 2004-03-22 | 2007-11-23 | Mars Inc | ANIMAL MASCADURE |
| WO2005092860A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds for the treatment of diseases |
| EA200601462A1 (en) | 2004-03-23 | 2007-04-27 | Пфайзер Инк. | CONNECTIONS FOR THE TREATMENT OF DISEASES |
| WO2005092841A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| PL1730103T3 (en) | 2004-03-23 | 2010-10-29 | Pfizer | Formamide derivatives useful as adrenoceptor |
| JP4775259B2 (en) | 2004-03-31 | 2011-09-21 | 味の素株式会社 | Aniline derivative |
| EP1789394A1 (en) | 2004-05-13 | 2007-05-30 | Boehringer Ingelheim International Gmbh | Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases |
| EP1595873A1 (en) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituted cycloalkyl derivatives for the treatment of respiratory diseases |
| DE102004024451A1 (en) | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder formulations for inhalation containing enantiomerically pure beta agonists |
| DE102004024454A1 (en) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals |
| CA2569395A1 (en) | 2004-06-03 | 2005-12-22 | Theravance, Inc. | Diamine .beta.2 adrenergic receptor agonists |
| JP2008507532A (en) | 2004-07-21 | 2008-03-13 | セラヴァンス， インコーポレーテッド | Diaryl ether β2 adrenergic receptor agonist |
| CA2573362A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| WO2006016245A1 (en) | 2004-08-05 | 2006-02-16 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2006031556A2 (en) | 2004-09-10 | 2006-03-23 | Theravance. Inc. | Amidine substituted aryl aniline compounds |
| DE102004045648A1 (en) | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New betamimetics for the treatment of respiratory diseases |
| WO2006051373A1 (en) | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| WO2006065788A2 (en) * | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Novel muscarinic acetylcholine receptor antagonists |
| JP5322935B2 (en) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | Inhibitors of plasma kallikrein |
-
2009
- 2009-10-28 GB GBGB0918924.2A patent/GB0918924D0/en not_active Ceased
-
2010
- 2010-10-27 WO PCT/GB2010/001997 patent/WO2011051672A1/en active Application Filing
- 2010-10-27 TW TW099136788A patent/TW201120038A/en unknown
- 2010-10-27 UY UY0001032976A patent/UY32976A/en unknown
- 2010-10-28 AR ARP100103979A patent/AR078818A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY32976A (en) | 2011-05-31 |
| GB0918924D0 (en) | 2009-12-16 |
| WO2011051672A1 (en) | 2011-05-05 |
| TW201120038A (en) | 2011-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2564179T3 (en) | Derivatives of 4- (p-quinonyl) -2-hydroxybutanamide for the treatment of mitochondrial diseases | |
| AR084849A1 (en) | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| CL2014003181A1 (en) | Compounds derived from n-substituted benzamides or n-substituted pyridinamides; pharmaceutical composition that includes them; treatment method; and its use for the treatment of selected diseases or disorders of pain, depression and cardiovascular, respiratory or psychiatric diseases or combinations thereof. | |
| CO6251251A2 (en) | DERIVATIVES OF PIRAZINONA AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | |
| AR085960A1 (en) | 1,3-OXAZINES AS INHIBITORS OF THE BACE1 AND / OR THE BACE2 | |
| AR078157A1 (en) | DERIVATIVES OF PIRAZOL- [4,5-D] PIRROLO [2,3-B] PYRIDINE INHIBITORS OF JAK 2 THYROSINQUINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THE SAME IN THE TREATMENT OF CANCER | |
| AR061548A1 (en) | 3-AMINOPIRROLIDINO-4-REPLACED LACTAMAS AS INHIBITORS OF DIPEPTIDILPEPTIDASA IV (DPP-IV), PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME IN THE TREATMENT OF DIABETES II. | |
| CO6321265A2 (en) | COMPOUNDS OF 2-AMIDO-3-METHYL PIRROID PYRIMIDINONE PHENYL-REPLACED AS BACE-1 INHIBITORS COMPOSITIONS AND ITS USE | |
| PE20142456A1 (en) | OXAZOLIDIN-2-ONA COMPOUNDS AND USES OF THE SAME AS INHIBITORS OF PI3Ks | |
| AR079226A1 (en) | ESPIROINDOLINONA- PIRROLIDINAS, PREPARATION PROCESSES AND USE OF THE SAME FOR THE TREATMENT AND PROFILAXIS OF CANCER | |
| UY29002A1 (en) | NEW HIDANTOINE DERIVATIVES, PARASU PREPARATION PROCESSES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY | |
| AR056886A1 (en) | PIRROLOPIRIDINE COMPOUNDS REPLACED INHIBITORS OF KINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN THE TREATMENT OF CANCER | |
| AR086357A1 (en) | INDAZOL DERIVATIVES ACTIVE SUBSTITUTES AS QUINASE INHIBITORS | |
| ECSP12012293A (en) | CERTAIN AMINO-PYRIMIDINS, COMPOSITION OF THE SAME AND METHODS FOR THE USE OF THE SAME | |
| AR088226A1 (en) | HETEROCICLIC PIPERIDINIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| AR059328A1 (en) | DERIVATIVES OF ANTRANILAMIDA-2-AMINO-HETEROARENO-CARBOXAMIDA, A PROCESS FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THESE COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CETP MEDIATION | |
| AR070479A1 (en) | FUSIONED HETEROCICLIC DERIVATIVE AND ITS USE | |
| ECSP088114A (en) | NEW DERIVATIVES OF 2-AZETIDINONE AND ITS USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR HYPERLIPIDEMIA TREATMENT | |
| AR071514A1 (en) | AMINOPIRIDINE DERIVATIVES | |
| AR069796A1 (en) | DERIVATIVES OF BENCIMIDAZOL, REPLACED BY CARBOXYL OR HYDROXYL, PROCESS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| EA201490726A1 (en) | PHARMACEUTICAL COMPOUNDS FOR USING CLOSTRIDIUM DIFFICILE INFECTION IN THERAPY | |
| AR083798A1 (en) | SELECTIVE INHIBITORS OF GLUCOSIDASES AND ITS USES | |
| AR084152A1 (en) | TRIAZOLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF PDE10A, A PROCESS FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF CNS DISEASES | |
| CU20090048A7 (en) | NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR077463A1 (en) | IMIDAZO DERIVATIVES [1, 2 - A] PIRAZINA AND ITS USE IN MEDICINES FOR THE TREATMENT OF PARASITARY DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |